Mark Manfredi, Ph.D.


Mark Manfredi is a founding member of Ikena Oncology and has over two decades of experience in cancer drug discovery and translational research. He previously served as Chief Scientific Officer of Raze Therapeutics and as Entrepreneur-in-Residence at Atlas Venture, and prior to that served as Vice President of Oncology at Takeda Pharmaceuticals where he was a member of the senior R&D management team responsible for global oncology R&D strategy. During his time at Takeda, the Oncology organization advanced eight novel mechanisms into the clinic, including ixazomib, which was recently approved by the FDA for the treatment of multiple myeloma. Mark is currently an advisor at Atlas Venture. He earned his B.S. from the University of Rhode Island and his Ph.D. in Biology from Boston College.

Scroll to Top